STAGE II HEPATOCELLULAR CARCINOMA AJCC V8
Clinical trials for STAGE II HEPATOCELLULAR CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE II HEPATOCELLULAR CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE II HEPATOCELLULAR CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise in shrinking High-Risk liver tumors
Disease control OngoingThis phase 2 trial tests whether combining regorafenib (a drug that blocks cancer cell growth) with durvalumab (an immunotherapy that helps the immune system attack cancer) can shrink tumors in people with high-risk liver cancer. The study includes 4 adults with early-stage liver…
Matched conditions: STAGE II HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
New drug cocktail aims to stop liver cancer comeback after surgery
Disease control OngoingThis study tests whether giving two drugs (atezolizumab and bevacizumab) before surgery can help prevent liver cancer from coming back. Sixteen adults with liver cancer that can be surgically removed will receive the drug combination. The goal is to see if the treatment can shrin…
Matched conditions: STAGE II HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 12, 2026 12:05 UTC